SHR-6209

Developed for: female breast carcinoma · hormone receptor-positive breast cancer
Investigated by: Affiliated Hospital of Nantong University · Chongqing University Cancer Hospital · First Affiliated Hospital Xi'an Jiaotong University · First Hospital of China Medical University · Fudan University · Fujian Medical University Union Hospital
+9 more
· Liaoning Cancer Hospital & Institute · Nanchang People's Hospital · Ningbo Medical Center Lihuili Hospital · Northern Jiangsu People's Hospital · Peking University Cancer Hospital & Institute · Shanghai 6th People's Hospital · Shanghai First Maternity and Infant Hospital · Sun Yat-sen University · The First Hospital of Jilin University

today NCT05594095 · Ph 2

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05594095	Dec 2022 → Dec 2025 overdue	female breast carcinoma, hormone receptor-positive breast cancer	Fudan University	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	SHR-6209	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594095 ↗